MA49144A - Polythérapies pour le traitement du cancer - Google Patents
Polythérapies pour le traitement du cancerInfo
- Publication number
- MA49144A MA49144A MA049144A MA49144A MA49144A MA 49144 A MA49144 A MA 49144A MA 049144 A MA049144 A MA 049144A MA 49144 A MA49144 A MA 49144A MA 49144 A MA49144 A MA 49144A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapies
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508363P | 2017-05-18 | 2017-05-18 | |
| US201762508481P | 2017-05-19 | 2017-05-19 | |
| US201762578204P | 2017-10-27 | 2017-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49144A true MA49144A (fr) | 2020-03-25 |
Family
ID=62705671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049144A MA49144A (fr) | 2017-05-18 | 2018-05-18 | Polythérapies pour le traitement du cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11622961B2 (fr) |
| EP (1) | EP3624850A1 (fr) |
| JP (1) | JP2020520921A (fr) |
| KR (1) | KR20200005662A (fr) |
| CN (1) | CN110913911A (fr) |
| AU (2) | AU2018270112A1 (fr) |
| BR (1) | BR112019024135A2 (fr) |
| CA (1) | CA3063715A1 (fr) |
| IL (1) | IL270720A (fr) |
| MA (1) | MA49144A (fr) |
| MX (1) | MX2019013755A (fr) |
| WO (1) | WO2018213732A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| JP6802791B2 (ja) | 2014-12-04 | 2020-12-23 | ヤンセン バイオテツク，インコーポレーテツド | 急性骨髄性白血病の治療のための抗ｃｄ３８抗体 |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| MD3827845T2 (ro) | 2015-11-03 | 2022-09-30 | Janssen Biotech Inc | Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3600314A1 (fr) | 2017-03-27 | 2020-02-05 | Tesaro, Inc. | Compositions de niraparib |
| CN118271233A (zh) | 2017-04-24 | 2024-07-02 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| US12156872B2 (en) | 2017-05-09 | 2024-12-03 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3063715A1 (fr) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Polytherapies pour le traitement du cancer |
| CA3076907A1 (fr) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Formulations de niraparib |
| CN111372607A (zh) | 2017-09-30 | 2020-07-03 | 特沙诺有限公司 | 用于治疗癌症的联合疗法 |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| CA3090479A1 (fr) * | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Formulations pediatriques de niraparib et procedes de traitement pediatrique |
| WO2020047651A1 (fr) * | 2018-09-04 | 2020-03-12 | Trillium Therapeutics Inc. | Blocage du cd47 avec inhibition de la parp pour le traitement de maladies |
| WO2020072796A1 (fr) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Formes cristallines d'une base libre de niraparib |
| US20220128544A1 (en) * | 2019-02-13 | 2022-04-28 | Creatv Microtech, Inc. | Ccr5-based methods for predicting overall and progression free survival in subjects having cancer |
| US20220319704A1 (en) | 2019-05-06 | 2022-10-06 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| CN115697324B (zh) * | 2020-02-20 | 2025-03-25 | 皇家学术促进会/麦吉尔大学 | 栗木鞣花素或其类似物用于抗癌功效和增加对免疫检查点抑制剂的应答的用途 |
| EP4112049A4 (fr) * | 2020-02-24 | 2024-07-24 | Fukang (Shanghai) Health Technology Co., Ltd. | Application anti-coronavirus de l'inhibiteur de la poly adp-ribose polymérase |
| US20230123585A1 (en) * | 2020-03-03 | 2023-04-20 | The University Of Chicago | Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors |
| CN117042767A (zh) * | 2021-02-11 | 2023-11-10 | 丹娜法伯癌症研究院 | 使用sting激动剂治疗癌症的方法 |
| US20220275090A1 (en) * | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| WO2022218264A1 (fr) * | 2021-04-11 | 2022-10-20 | Adagene Inc. | Polythérapies pour le traitement du cancer |
| WO2022271547A1 (fr) | 2021-06-21 | 2022-12-29 | Tesaro, Inc. | Traitement combiné du cancer avec un inhibiteur de parp et une statine lipophile |
| WO2023048506A1 (fr) * | 2021-09-23 | 2023-03-30 | 국립암센터 | Composition pharmaceutique pour la prévention ou le traitement du cancer comprenant un inhibiteur de la carnitine-acylcarnitine translocase et un agent anticancéreux |
| TW202337897A (zh) * | 2021-11-18 | 2023-10-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法 |
| WO2023133409A2 (fr) * | 2022-01-04 | 2023-07-13 | Cornell University | Polythérapies comprenant des inhibiteurs de parp1 |
| CN119156216A (zh) | 2022-02-15 | 2024-12-17 | 特沙诺有限公司 | 尼拉帕尼用于治疗脑癌的用途 |
| CN116370607A (zh) * | 2023-03-20 | 2023-07-04 | 中国人民解放军陆军军医大学第一附属医院 | 人重组hmgb1在制备治疗胶质瘤化疗增敏剂中的应用 |
| WO2024216089A1 (fr) * | 2023-04-13 | 2024-10-17 | Bolt Biotherapeutics, Inc. | Polythérapie à base d'anticorps anti-dectine-2 |
| CN118718000A (zh) * | 2023-06-19 | 2024-10-01 | 上海市第六人民医院 | 药物组合物及其在制备治疗肾癌的药物中的用途 |
| CN116726187B (zh) * | 2023-07-26 | 2025-09-30 | 珠海市人民医院 | 一种小分子配体-鲁卡帕尼偶联物及其制备方法 |
| KR20250156324A (ko) * | 2024-04-25 | 2025-11-03 | 한국 한의학 연구원 | 루카파립 캄실레이트를 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2059571T3 (es) | 1988-01-19 | 1994-11-16 | Takeda Chemical Industries Ltd | Fumagilina como agente angiostatico. |
| EP0357061B1 (fr) | 1988-09-01 | 1994-06-08 | Takeda Chemical Industries, Ltd. | Agent inhibiteur d'angiogenèse |
| EP2206517B1 (fr) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Compositions immunostimulantes contenant un anticorps anti-PD-L1 |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| CA2647545C (fr) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Utilisation de derives de benzotriazole et d'indazole amide substitue comme inhibiteurs de la poly(adp-ribose)polymerase (parp) |
| EP2805945B1 (fr) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| JP2011503111A (ja) | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| CA2705417A1 (fr) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Traitement du cancer de l'uterus et du cancer de l'ovaire avec un inhibiteur parp utilise seul ou en combinaison avec des antitumoraux |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| EP2237684A2 (fr) | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonistes pour des systèmes peptidiques antimicrobiens |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| US20120130144A1 (en) | 2009-02-04 | 2012-05-24 | Bipar Sciences, Inc. | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| WO2011153383A1 (fr) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Procédés de traitement d'un cancer des ovaires récurrent et résistant au platine avec du 4-iodo-3-nitrobenzamide en combinaison avec un antimétabolite et un composé de platine. |
| DK2582847T3 (en) | 2010-06-18 | 2016-12-19 | Myriad Genetics Inc | METHODS AND MATERIALS TO ASSESS loss of heterozygosity |
| WO2012027224A1 (fr) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Méthodes de prédiction d'une réponse anticancéreuse |
| CA2742342A1 (fr) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Le statut a l'egard de l'expression de msh3 determine le degre de reponse des cellules cancereuses a un traitement chimiotherapeutique faisant intervenir des inhibiteurs de la parp et des medicaments a base de platine |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013182645A1 (fr) | 2012-06-07 | 2013-12-12 | Institut Curie | Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines |
| US9738915B2 (en) | 2012-12-07 | 2017-08-22 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| US9850542B2 (en) | 2013-03-04 | 2017-12-26 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (HR) deficient cancer |
| US20150071910A1 (en) | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| CA2931181C (fr) | 2013-12-09 | 2023-01-24 | Institut Curie | Procede pour la detection de l'inactivation de voie de recombinaison homologue (brca1/2) dans des tumeurs humaines |
| JP6663350B2 (ja) | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー，インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
| WO2015116868A2 (fr) | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Profilage moléculaire de modulateurs immunitaires |
| US10238630B2 (en) | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| EP3230472A4 (fr) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Méthodes et matériaux permettant de prédire une réaction au niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| CN107847589B (zh) | 2015-04-01 | 2022-03-29 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体 |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| PL3337467T3 (pl) | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| JP2018536700A (ja) | 2015-10-26 | 2018-12-13 | メディヴェイション テクノロジーズ， エルエルシー | Ｐａｒｐ阻害剤を用いる小細胞肺がんの治療 |
| EP4071174A1 (fr) | 2016-02-15 | 2022-10-12 | AstraZeneca AB | Procédés comprenant un dosage intermittent et fixe de cediranib |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
| BR112019008861A2 (pt) | 2016-11-01 | 2019-07-09 | Tesaro, Inc. | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| EP3666794A1 (fr) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Anticorps dirigés contre la mort programmée 1 (pd -1) |
| SG10201913083SA (en) | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| EP3600314A1 (fr) | 2017-03-27 | 2020-02-05 | Tesaro, Inc. | Compositions de niraparib |
| BR112019020191A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro Inc | formulações de niraparib |
| CN118271233A (zh) | 2017-04-24 | 2024-07-02 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| SG10201913677SA (en) | 2017-04-27 | 2020-03-30 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| US12156872B2 (en) | 2017-05-09 | 2024-12-03 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3063715A1 (fr) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Polytherapies pour le traitement du cancer |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| CA3076907A1 (fr) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Formulations de niraparib |
| CN111372607A (zh) | 2017-09-30 | 2020-07-03 | 特沙诺有限公司 | 用于治疗癌症的联合疗法 |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| EP3731866A1 (fr) | 2017-12-27 | 2020-11-04 | Tesaro Inc. | Méthodes de traitement du cancer |
| CA3090479A1 (fr) | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Formulations pediatriques de niraparib et procedes de traitement pediatrique |
| EA201992594A1 (ru) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | Комбинированные терапии для лечения рака |
| US11970530B2 (en) | 2020-08-13 | 2024-04-30 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-05-18 CA CA3063715A patent/CA3063715A1/fr active Pending
- 2018-05-18 AU AU2018270112A patent/AU2018270112A1/en not_active Abandoned
- 2018-05-18 CN CN201880047169.9A patent/CN110913911A/zh active Pending
- 2018-05-18 EP EP18733393.5A patent/EP3624850A1/fr not_active Withdrawn
- 2018-05-18 WO PCT/US2018/033437 patent/WO2018213732A1/fr not_active Ceased
- 2018-05-18 KR KR1020197037232A patent/KR20200005662A/ko not_active Ceased
- 2018-05-18 MX MX2019013755A patent/MX2019013755A/es unknown
- 2018-05-18 US US16/614,131 patent/US11622961B2/en active Active
- 2018-05-18 BR BR112019024135-3A patent/BR112019024135A2/pt not_active IP Right Cessation
- 2018-05-18 JP JP2019563582A patent/JP2020520921A/ja active Pending
- 2018-05-18 MA MA049144A patent/MA49144A/fr unknown
-
2019
- 2019-11-17 IL IL270720A patent/IL270720A/en unknown
-
2021
- 2021-08-09 AU AU2021215113A patent/AU2021215113A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200005662A (ko) | 2020-01-15 |
| CN110913911A (zh) | 2020-03-24 |
| WO2018213732A1 (fr) | 2018-11-22 |
| EP3624850A1 (fr) | 2020-03-25 |
| US11622961B2 (en) | 2023-04-11 |
| CA3063715A1 (fr) | 2018-11-22 |
| AU2021215113A1 (en) | 2021-08-26 |
| US20210008053A1 (en) | 2021-01-14 |
| JP2020520921A (ja) | 2020-07-16 |
| AU2018270112A1 (en) | 2019-12-12 |
| IL270720A (en) | 2020-01-30 |
| MX2019013755A (es) | 2020-07-20 |
| BR112019024135A2 (pt) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3431105A4 (fr) | Composition médicinale pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3452060A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3397963A4 (fr) | Inhibition de mapk p38 pour le traitement du cancer | |
| EP3494142A4 (fr) | Anticorps anti-siglec-7 pour le traitement du cancer | |
| EP3432927A4 (fr) | Inhibiteurs trispécifiques pour le traitement du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| EP3436002A4 (fr) | Combinaisons pharmaceutiques pour le traitement du cancer | |
| EP3368559A4 (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3285773A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3400010A4 (fr) | Combinaisons anti-her2 pour le traitement des tumeurs | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3359192A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3474854A4 (fr) | Associations médicamenteuses pour le traitement du cancer | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3541417A4 (fr) | Immunothérapies d'association pour le traitement du cancer | |
| EP3331510A4 (fr) | Thérapies combinatoires pour le traitement du cancer | |
| EP3462883A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
| EP3503887A4 (fr) | Combinaisons pour le traitement du cancer |